Stryker's Trevo stroke device hot on Covidien's heels with positive pivotal data

A pivotal trial of Stryker's Trevo, a device for removing clots in the blood vessels of ischaemic stroke patients, has met its primary endpoint, paving the way for US approval. Stryker plans to use the data from the study, TREVO 2, in a 510(k) application with the FDA; the firm previously told Clinica that it anticipates clearance in late 2012 or early 2013 (www.clinica.co.uk, 1 December 2011).